{
     "PMID": "14993421",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20040510",
     "LR": "20170419",
     "IS": "1534-0384 (Print) 1534-0384 (Linking)",
     "VI": "3",
     "IP": "3",
     "DP": "2003 May",
     "TI": "Galanin in Alzheimer disease.",
     "PG": "137-56",
     "AB": "Galanin (GAL) and GAL receptors (GALR) are overexpressed in limbic brain regions associated with cognition in Alzheimer disease (AD). The functional consequences of this overexpression are unclear. Because GAL inhibits cholinergic transmission and restricts long-term potentiation in the hippocampus, GAL overexpression may exacerbate clinical features of AD. In contrast, GAL expression increases in response to neuronal injury, and galaninergic hyperinnervation prevents the decreased production of protein phosphatase 1 subtype mRNAs in cholinergic basal forebrain neurons in AD. Thus, GAL may also be neuroprotective for AD. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands for the treatment of AD.",
     "FAU": [
          "Counts, Scott E",
          "Perez, Sylvia E",
          "Ginsberg, Stephen D",
          "De Lacalle, Sonsoles",
          "Mufson, Elliott J"
     ],
     "AU": [
          "Counts SE",
          "Perez SE",
          "Ginsberg SD",
          "De Lacalle S",
          "Mufson EJ"
     ],
     "AD": "Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, 2242 West Harrison Street, Chicago, IL 60612, USA. emufson@rush.edu",
     "LA": [
          "eng"
     ],
     "GR": [
          "AG19597/AG/NIA NIH HHS/United States",
          "CA94520/CA/NCI NIH HHS/United States",
          "R29 AG012401-06/AG/NIA NIH HHS/United States",
          "R01 AG043375/AG/NIA NIH HHS/United States",
          "AG14449/AG/NIA NIH HHS/United States",
          "R29 AG012401/AG/NIA NIH HHS/United States",
          "AG 09466/AG/NIA NIH HHS/United States",
          "TGAG000259/AG/NIA NIH HHS/United States",
          "NS43939/NS/NINDS NIH HHS/United States",
          "AG10688/AG/NIA NIH HHS/United States"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't",
          "Research Support, U.S. Gov't, P.H.S.",
          "Review"
     ],
     "PL": "United States",
     "TA": "Mol Interv",
     "JT": "Molecular interventions",
     "JID": "101093789",
     "RN": [
          "0 (RNA, Messenger)",
          "88813-36-9 (Galanin)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/*genetics/*metabolism/therapy",
          "Animals",
          "Brain/*metabolism/pathology",
          "Galanin/*physiology",
          "Humans",
          "Mice",
          "Models, Biological",
          "Prosencephalon/metabolism",
          "RNA, Messenger/metabolism"
     ],
     "RF": "160",
     "EDAT": "2004/03/03 05:00",
     "MHDA": "2004/05/11 05:00",
     "CRDT": [
          "2004/03/03 05:00"
     ],
     "PHST": [
          "2004/03/03 05:00 [pubmed]",
          "2004/05/11 05:00 [medline]",
          "2004/03/03 05:00 [entrez]"
     ],
     "AID": [
          "10.1124/mi.3.3.137 [doi]",
          "3/3/137 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Mol Interv. 2003 May;3(3):137-56. doi: 10.1124/mi.3.3.137.",
     "term": "hippocampus"
}